Clinical Lymphoma, Myeloma and Leukemia


Publication Venue For

  • Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma. 2021
  • Highlights of the Management of Adult Histiocytic Disorders: Langerhans Cell Histiocytosis, Erdheim-Chester Disease, Rosai-Dorfman Disease, and Hemophagocytic Lymphohistiocytosis.  21:e66-e75. 2021
  • Consensus Recommendations for the Clinical Management of Patients With Multiple Myeloma Treated With Selinexor.  20:351-357. 2020
  • Lenalidomide Plus Hypomethylating Agent as a Treatment Option in Acute Myeloid Leukemia With Recurrent Genetic Abnormalities—AML With inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM.  20:24-30. 2020
  • Observation Versus Immediate Reinduction for Acute Myeloid Leukemia Patients With Indeterminate Day 14 Bone Marrow Results.  20:31-38. 2020
  • Incidence, Clinical Features, and Outcomes of Langerhans Cell Sarcoma in the United States.  19:441-446. 2019
  • Histiocytic Sarcoma Associated With Follicular Lymphoma: Evidence for Dramatic Response With Rituximab and Bendamustine Alone and a Review of the Literature.  19:e1-e8. 2019
  • Clinicopathologic Features and Clinical Outcome Differences in De Novo Versus Secondary Histiocytic Sarcomas: A Multi-institutional Experience and Review of the Literature.  18:e427-e435. 2018
  • Surrogate Endpoints and Risk Adaptive Strategies in Previously Untreated Follicular Lymphoma.  18:447-451. 2018
  • Treatment Patterns and Outcomes in Early-stage Hodgkin Lymphoma in the Elderly: A National Cancer Database Analysis.  17:812-818. 2017
  • Outcome of Adolescents and Young Adults Compared With Pediatric Patients With Acute Myeloid and Promyelocytic Leukemia.  17:126-132.e1. 2017
  • Comorbidities Drive Outcomes for Both Malignancy-Associated and Non-Malignancy-Associated Hemophagocytic Syndrome.  16:230-236. 2016
  • Trends in Use of Radiation Therapy for Hodgkin Lymphoma from 2000 to 2012 on the Basis of the National Cancer Data Base.  16:12-17. 2016
  • Racial Differences in the Overall Survival of Hairy Cell Leukemia in the United States: A Population-Based Analysis of the Surveillance, Epidemiology, and End Results Database.  15:484-488. 2015
  • Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia - Results of a phase i dose-escalation study.  15:443-449. 2015
  • Influence of insurance and marital status on outcomes of adolescents and young adults with acute lymphoblastic leukemia.  15:364-367. 2015
  • Central Nervous System Complications and Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation.  15:606-611. 2015
  • How center volumes affect early outcomes in acute myeloid leukemia.  15:646-654. 2015
  • Lenalidomide-induced graft-Vs.-leukemia effect in a patient with chronic lymphocytic leukemia who relapsed after allogeneic stem cell transplant.  14. 2014
  • The development of a myeloablative, reduced-toxicity, conditioning regimen for cord blood transplantation.  14. 2014
  • A case of acute promyelocytic leukemia without RARα rearrangement and apparently normal cytogenetics.  11:521-524. 2011
  • Erratum: Ofatumumab, a novel CD20 monoclonal antibody, is active in patients with fludarabine- and alemtuzumab-refractory or bulky fludarabine-refractory chronic lymphocytic leukemia irrespective of prior rituximab (Clinical lymphoma & Myeloma (2009) 9: 6 (E36) DOI: 10.3816/CLM.2009.n.098).  10:157. 2010
  • International Standard Serial Number (issn)

  • 2152-2650
  • Electronic International Standard Serial Number (eissn)

  • 2152-2669